A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
Clinical trial NCT04211337 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04211337
- Sponsor
- Loxo Oncology, Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-02-11
- Primary completion
- 2023-05-22
- Enrollment
- 291
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.